TELL ME MORE
ABOUT THIS CLINICAL TRIAL for an INFANT MENINGOCOCCAL VACCINE
This is an Immunogenicity and Safety Study of a Quadrivalent Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants age 42 – 89 days old

Infant Meningococcal Vaccine
Study Location(s): Evansville Indiana
This study evaluates the safety and immunogenicity of a 4-dose series of the quadrivalent Meningococcal Polysaccharide (Serogroups A, C, Y, and W) in healthy infants and toddlers in comparison to MENVEO® when both are administered concomitantly with routine pediatric vaccines. Click here for more information on Meningococcal vaccines.
There is no cost to participate. Volunteers receive free vaccines and follow-up care. No insurance needed. Time and travel reimburrsement up to $400 may be available.
Watch a 2-minute video about Infant Meningococcal Vaccine
View More Studies
Condition | Location | Status | Age Range | Sex | Max Compensation | |
---|---|---|---|---|---|---|
ACNE HYPERPIGMENTATION Trifarotene Cream used versus another cream to treat acne-induced hyperpigmentation | Evansville | Enrolling | 13-35 | $750 | Request Info | |
ADHD A Long-term active comparitor and dose optimization study to evaluate safety and efficacy of a non-stimulat medication | Bowling Green Owensboro | Enrolling | 6 - 17 | $1150 | Request Info | |
COPD Safety, Efficacy and Tolerance study for moderate to severe COPD | Owensboro | Coming Soon | 40-85 | Up to $750 | Request Info | |
DIABETES (T2DM) Safety and Efficacy of an Investigational Medicine for pediatric and adolescent patients with type 2 diabetes. | Evansville | Enrolling | 10-17 | Up to $875 | Request Info | |
DIABETES (T2DM) Study to Evaluate the Efficacy and Safety of an Investigation Medication as a Weekly Basal Insulin Compared to Insulin Degludec in Insulin Naïve Adults with Type 2 Diabetes | Bowling Green Evansville Owensboro | Coming Soon | 18 Years & Up | $1625 | Request Info | |
ECZEMA (Atopic Dermatitis) Safety and efficacy, placebo-controlled study of a topical investigational medicine with open-label extension in patients with moderate to severe eczema | Owensboro | Enrolling | 2+ (child through adult) | $490 | Request Info | |
ECZEMA (Atopic Dermatitis) Safety and efficacy, placebo-controlled study of a topical investigational medicine with open-label extension in patients with moderate to severe eczema | Evansville | Enrolling | 2+ (child through adult) | $560 - $1400 | Request Info | |
IBD - CROHN'S DISEASE A Safety and efficacy, placebo-controlled and active-controlled comparison study for patients with moderate to severe Crohn's Disease | Owensboro Evansville | Enrolling | 18 - 80 | $3200 | Request Info | |
IBD - ULCERATIVE COLITIS A Safety and efficacy, placebo-controlled and active-controlled comparison study for patients with moderate to severe Ulcerative Colitis | Evansville | Recruiting | 18 - 80 | $1100 | Request Info | |
INFANT FORMULA & BREASTFEEDING Infant Formula for Healthy Babies | Evansville Owensboro | Enrolling | Newborns | $625 + formula | Request Info | |
LUPUS (SLE) A Randomized, Placebo-Controlled Clinical Trial for the Treatment of Systemic Lupus Erythematosus | Evansville | Enrolling | 18 - 65 | $800 | Request Info | |
LUPUS NEPHRITIS A Safety, efficacy and tolerability study for patients with active Lupus Nephritis | Evansville | Enrolling | 18 - 75 | $4625 ($125 per visit) | Request Info | |
MIGRAINES in CHILDREN A Double Blind, Placebo Controlled Study of an Investigational Medicine for Pediatric Migraines | BowlingGreen Owensboro Evansville | Enrolling | 6 - 17 | $200/$350 | Request Info | |
MENINGOCOCCAL VACCINE Safety and Immunogenicity of a Meningococcal B vaccine when Administered Together with the MENVEO (MenACWY) Vaccine in healthy subjects age 16 - 18 | Evansville | Enrolling | 16-18 | $300 | Request Info | |
PSORIASIS A Double-blind, Placebo-controlled Study to Investigate the Efficacy of an Investigational Oral Medication of Moderate to Severe Plaque Psoriasis | Owensboro Evansville | Enrolling | 18-75 | Up to $585 | Request Info | |